Rani Therapeutics Holdings (RANI) Non-Current Assets (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Non-Current Assets of $4.8 million for Q1 2026, down 24.5% year-over-year from $6.3 million in Q1 2025, and down 9.66% quarter-over-quarter from $5.3 million in Q4 2025.
Rani Therapeutics Holdings (RANI) Non-Current Assets (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Non-Current Assets history runs 7 years deep, the most recent figure standing at $4.8 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 24.5% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $21.1 million (down 41.55% YoY), while the FY2025 annual figure was $5.3 million, down 23.08% from the prior year.
- Non-Current Assets for Q1 2026 stood at $4.8 million, down from $5.3 million in the prior quarter.
- The five-year high for Non-Current Assets was $12.1 million in Q1 2024, with the low at $4.8 million in Q1 2026.
- The 5-year median for Non-Current Assets is $7.1 million (2023), against an average of $7.4 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets soared 63.91% in 2024, then sank 53.59% in 2025.
- Rani Therapeutics Holdings' Non-Current Assets stood at $7.1 million in 2022, then declined by 0.48% to $7.1 million in 2023, then retreated by 2.53% to $6.9 million in 2024, then retreated by 23.08% to $5.3 million in 2025, then slipped by 9.66% to $4.8 million in 2026.
- Business Quant data shows RANI's Non-Current Assets at $4.8 million in Q1 2026, $5.3 million in Q4 2025, and $5.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 18.06 Bn |
| 10 | Rani Therapeutics Holdings | 161.19 Mn | 161.19 Mn | - | 4.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.32 Mn |
| Mar 31, 2026 | 4.79 Mn |
| Dec 31, 2025 | 5.30 Mn |
| Sep 30, 2025 | 5.18 Mn |
| Jun 30, 2025 | 5.83 Mn |
| Mar 31, 2025 | 6.34 Mn |
| Dec 31, 2024 | 6.89 Mn |
| Sep 30, 2024 | 11.17 Mn |
| Jun 30, 2024 | 11.69 Mn |
| Mar 31, 2024 | 12.12 Mn |
| Dec 31, 2023 | 7.07 Mn |
| Sep 30, 2023 | 7.21 Mn |
| Jun 30, 2023 | 7.13 Mn |
| Mar 31, 2023 | 7.41 Mn |
| Dec 31, 2022 | 7.10 Mn |
| Sep 30, 2022 | 7.48 Mn |
| Jun 30, 2022 | 6.35 Mn |
| Mar 31, 2022 | 6.05 Mn |
| Dec 31, 2021 | 4.61 Mn |
| Sep 30, 2021 | 4.59 Mn |